Fibrolamellar carcinoma as a distinct subtype of hepatocellular carcinoma: molecular genetics features, diagnostics and treatment prospects

Fibrolamellar carcinonoma (FLC) was described in 1956 as a separate subtype of hepatocellular carcinoma (HCC) that affects young adults without underling liver diseases. Morphologically FLC is characterized as HCC with large cells, gross nucleus and fibrous collagen bands organized into branched net. The mechanisms of FLC development in the absence of major risk factors remained obscured for a considerable amount of time. High-throughput transcriptomic analysis allowed to describe the unique profile of gene expression in FLC and to define the main signaling pathways activated in tumor cells which include mTOR, FGFR и EGFR cascades which can be accounted as potential therapeutic targets for this type of tumors. Whole transcriptome sequencing allowed to identify in the majority of FLC samples the new chimeric transcript DNAJB1-PRKACA which appears due to deletion of the part of chromosome 19 which leads to fusion of two genes. This translocation appears to be driving event in FLC development that governs increase of proliferation, colony formation and tumor stem cells population. Fusion transcript is specific for FLC and can be identified through the number of clinical laboratory methods. It opens the opportunity for use of that fusion in differential diagnostics as FLC marker. Due to kinase activity of DNAJB1-PRKACA protein, it is considered to be prospective target for the development of therapeutic compounds which can inhibit this function. Analysis of transcriptome aberrations in FLC allowed to specify the prognostic signature of 8 genes whose overexpression correlates with poor patient survival after the surgery. In this review we have summarized recent data on FLC molecular pathogenesis and possibilities for the development of new methods for diagnosis and treatment based on these findings.

1. Llovet J. M., Zucman-Rossi J., Pikarsky E. et al. Hepatocellular carcinoma, Nature Reviews Disease Primers, 2016, Vol. 2, p. 16018.

2. Лазаревич Н. Л., Кривцова О. М., Сковородникова П. А. Молекулярно-генетические особенности клинического прогноза ГЦР // Злокачественные опухоли. 2016. Т. 4 (1), С. 40–45. [Lazarevich N. L., Krivtsova O. M.,

3. Skovorodnikova P. A. Molekulyarno-geneticheskie osobennosti klinicheskogo prognoza GTsR, Zlokachestvennye opukholi, 2016, Vol. 4 (1), pp. 40–45 (In Russ.)].

4. Zucman-Rossi J., Villanueva A., Nault J-C., Llovet J. M. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma, Gastroenterology, 2015, Vol. 149 (5), pp. 1226–1239.

5. Lee J. S., Heo J., Libbrecht L. et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nat. Med., 2006, Vol. 12 (4), pp. 410–416.

6. Hoshida Y., Nijman S. M., Kobayashi M. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res., 2009, Vol. 69 (18), pp. 7385–7392.

7. Edmondson H. A. Differential diagnosis of tumors and tumor-like lesions of the liver in infancy and childhood, Am. J. Dis. Child., 1956, Vol. 91, pp. 168–186.

8. Torbenson M. S. Review of the Clinicopathologic Features of Fibrolamellar Carcinoma, Adv. Anat. Pathol., 2007, Vol. 14, pp. 217–223.

9. Honeyman J. N., Simon E. P., Robine N. et al. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma, Science, 2014, Vol. 343, p. 1010.

10. Sergi C. M. Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update, A Primer, Diagnostics, 2015, Vol. 6 (1), pii: E3.

11. Torbenson M. S. Morphologic Subtypes of Hepatocellular Carcinoma, Gastroenterol. Clin. N. Am., 2017, Vol. 46, pp. 365–391.

12. Serg C. M. Fibrolamellar Carcinoma: A Distinct Variant of Hepatocellular Carcinoma That Is Still Surrounded by Unveils Mysteries, J. Cancer Ther., 2014, Vol. 5, pp. 1325–1331.

13. Ward S. C., Huang J., Tickoo S. K. et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation, Mod. Pathol., 2010, Vol. 23, pp. 1180–1190.

14. Abelev G. I., Eraiser T. L. Cellular aspects of alpha-fetoprotein reexpression in tumors, Semin. Cancer Biol., 1999, Vol. 9 (2), pp. 95-107.

15. Torbenson M. Fibrolamellar carcinoma: 2012 update, Scientifica (Cairo), 2012, Vol. 2012, 743790.

16. de Boer C. J., van Krieken J. H. J. M., Janssen-van Rhijn C. M., Litvinov S. V. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver, J. Pathol., 1999, Vol. 188, pp. 201–206.

17. Gires O. EpCAM in hepatocytes and their progenitors, J. Hepatol., 2012, Vol. 56 (2), pp. 490–492.

18. Graham R. P., Torbenson M. S. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings, Semin. Diagn. Pathol., 2017, Vol. 34 (2), pp. 146–152.

19. Eggert T., McGlynn K. A., Duffy A. et al. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterol. J., 2013, Vol. 1 (5), pp. 351–357.

20. Mayo S. C., Mavros M. N., Nathan H. et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J. Am. Coll. Surg., 2014, Vol. 218 (2), pp. 196–205.

21. Kannangai R., Vivekanandan P., Martinez-Murillo F., Choti M., Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways, Hum. Pathol., 2007, Vol. 38 (4), pp. 639–644.

22. Buckley A. F., Burgart L. J., Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma, Hum. Pathol., 2006, Vol. 37, pp. 410–414.

23. Andrechek E. R. HER2 / Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors, Oncogene, 2015, Vol. 34 (2), pp. 217–225.

24. Oeggerli M., Schraml P., Ruiz C. et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer, Oncogene, 2006, Vol. 25 (49), pp. 6538–6543.

25. Riehle K. J., Yeh M. M., Yu J. J. et al. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma, Mod. Pathol., 2015, Vol. 28, pp. 103–110.

26. Simon E. P., Freije C. A., Farbe B. A. et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma, Proc. Natl. Acad. Sci., 2015, Vol. 112 (44), E5916–5925.

27. Oikawa T., Wauthier E., Dinh T. A. et al. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells, Nat. Commun., 2015, Vol. 6, p. 8070.

28. Graham R. P., Jin L., Knutson D. L. et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma, Modern Pathology, 2015, Vol. 28 (6), pp. 822–829.

29. Kim C., Xuong N. H., Taylor S. S. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA, Science, 2005, Vol. 307 (5710), pp. 690–696.

30. Cheung J., Ginter C., Cassidy M. et al. Structural insights into mis-regulation of protein kinase A in human tumors, Proc. Natl. Acad. Sci., 2015, Vol. 112 (5), pp. 1374–1379.

31. Cao Y., He M., Gao Z. et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing”s syndrome, Science, 2014, Vol. 344 (6186), pp. 913–917.

32. Kirschner L. S., Carney J. A., Pack S. D. et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex, Nat. Genet., 2000, Vol. 26, pp. 89–92.

33. Riggle K. M., Riehle K. J., Kenerson H. L. et al. Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma, Pediatr. Res., 2016, Vol. 80 (1), pp. 110–118.

34. Xu L., Hazard F. K., Zmoos A. F. et al. Genomic analysis of fibrolamellar hepatocellular carcinoma, Hum. Mol. Genet., 2014, pii: ddu418.

35. Kastenhuber E. R, Lalazar G., Tschaharganeh D. F. et al. DNAJB1-PRKACA fusion kinase drives tumorigenesis and interacts with -catenin and the liver regenerative response, 2017, bioRxiv 192104, http://dx.doi.org / 10.1101 / 192104.

36. Dinh T. A., Vitucci E. C., Wauthier E. et al. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma, Sci. Rep., 2017, Vol. 7, 44653.

37. Torbenson M., Kannangai R., Abraham S. et al. Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma, Am. J. Clin. Pathol., 2004, Vol. 122 (3), pp. 377–382.

38. Sorenson E. C., Khanin R., Bamboat Z. M. et al. Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation, PLoS One, 2017, Vol. 12 (5), e0176562.

39. Malouf G. G., Job S., Paradis V. et al. Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature, Hepatology, 2014, Vol. 59 (6), pp. 2228–2237.

40. Cornella H., Alsinet C., Sayols S. et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma, Gastroenterology, 2015, Vol. 148 (4), 806–818. e10.

41. Abou-Alfa G. K. Mayer R. J., Cosgrove D. et al. Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC), Journal of Clinical Oncology, 2015, Vol. 33, 15, suppl, e15149-e15149.